AbbVie Inc. (BCBA: ABBV)

Market Cap	324.42T
Revenue (ttm)	53.86T
Net Income (ttm)	4.93T
Shares Out	n/a
EPS (ttm)	2,783.24
PE Ratio	65.84
Forward PE	n/a
Dividend	441.54 (2.12%)
Ex-Dividend Date	Jan 15, 2025

Volume	833
Average Volume	1,262
Open	20,075
Previous Close	19,900
Day's Range	20,000 - 20,850
52-Week Range	11,997 - 26,225
Beta	n/a
RSI	54.18
Earnings Date	Jan 31, 2025

About AbbVie

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; E...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 50,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2023, AbbVie's revenue was $54.32 billion, a decrease of -6.44% compared to the previous year's $58.05 billion. Earnings were $4.82 billion, a decrease of -59.09%.

Financial numbers in USD